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OBJECTIVE: The association between polycystic ovarian syndrome and increased cardiovascular disease risk is still a controversial 
issue. In light of data documenting some common pathways or common end-points, the present study was undertaken to determine 
whether there is a relationship between sleep blood pressure pattern disturbances and polycystic ovarian syndrome in young women.
METHOD: The daytime and nighttime ambulatory blood pressures (BPs) were determined for each subject, according to the actual 
waking and sleeping times recorded in their individual diaries, in this cross-sectional study.
RESULTS: The study group comprised 168 women (mean age: 25.7±5.5) diagnosed with polycystic ovarian syndrome, while the 
control group included 52 age- and BMI-matched healthy subjects (mean age: 26.1±5.4). When nocturnal BP declines very little or 
not at all, with the BP falling less than 10% during sleep compared with waking values, this pattern is classified as a non-dipping BP 
pattern. However, the non-dipping pattern of BP changes was significantly more common in polycystic ovarian syndrome patients 
compared to the control group (p<0.01). The prevalence of a non-dipping BP pattern was 43.4% (73 patients) in polycystic ovarian 
syndrome patients and 3.9% (2 patients) in the control group. 
CONCLUSION: Our cross-sectional study revealed that a non-dipping BP pattern is highly prevalent in polycystic ovarian syn-
drome patients, even if they are young and non-obese. 
KEYWORDS: Polycystic ovary syndrome; non-dipping blood pressure.
INTRODUCTION
Polycystic  ovarian  syndrome  (PCOS),  which 
affects 5–10% of women of reproductive age, has some 
characteristic clinical features, including amenorrhea, 
oligomenorrhea or other irregular uterine bleeding, 
hirsutism, acne, and/or obesity.1,2 Unfortunately, patients with 
PCOS have an increased risk for type 2 diabetes mellitus, 
endometrial carcinoma, and spontaneous abortions.3,4 
Moreover, a clear association between PCOS and increased 
cardiovascular disease has been reported in many recent 
studies.5
A 3.3-fold higher risk of cardiovascular death or 
myocardial infarction in postmenopausal women with 
clinical features of PCOS has been reported recently.6 The 
suspected link between PCOS and cardiovascular disease 
is insulin resistance, which plays a central role not only 
in PCOS development but also in metabolic syndrome, 
a common syndrome that constitutes a combination 
of disturbances of carbohydrate and lipid metabolism, 
increased waist circumference, and hypertension. In addition 
to impaired endothelial-dependent vasodilatation, both 
increased carotid intima media wall thickness and amplified 
pulse-wave velocity have been established in PCOS as early 
clinical markers of atherosclerosis.7-9 Moreover, several 
markers of cardiovascular risk, such as tumor necrosis 
factor-α, homocysteine, plasminogen activator inhibitor-1, 476
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and highly sensitive C-reactive protein (hsCRP), are 
increased in women with PCOS.10,11 
When nocturnal blood pressure (BP) declines very little 
or not at all, with the BP falling less than 10% during sleep 
compared with waking values, this pattern is classified as 
a non-dipping BP pattern. Because non-dippers have an 
elevated risk of target organ damage and increased incidence 
of fatal and non-fatal cardiovascular events compared to 
dippers, much attention has been given to the 24-hour 
BP patterns.12-13 Although the exact mechanisms are still 
not clear, endothelial impairment and oxidative stress 
may contribute to the non-dipping BP pattern, autonomic 
dysfunction, obesity, and insulin resistance.14-16
In light of the data documenting some common pathways 
or common end-points for non-dipping BP pattern and 
PCOS, the present study was undertaken to determine 
whether there is a relationship between sleep BP pattern 
disturbances and PCOS in young women. 
METHODS
Study design
The study was carried out at Fatih University Hospital. 
A cross-sectional study design was used to compare the 
prevalence of a non-dipping BP pattern in healthy women 
and women with PCOS. The patients and controls were 
individually matched for age and body mass index (BMI). 
This study was approved by the Fatih University 
School of Medicine Ethics Committee and was conducted 
in accordance with the ethical principles described by the 
Declaration of Helsinki. Written informed consent was 
obtained from all participants.
Subjects 
Our study included consecutive outpatients admitted to 
the Department of Endocrinology of Fatih University, Turkey 
between January to July 2009 and who were diagnosed with 
PCOS. Age- and BMI-matched subjects were used as the 
control group. 
The diagnosis of PCOS was based on the revised 2003 
consensus on diagnostic criteria and long-term health risks 
related to PCOS published by the Rotterdam ESHRE/
ASRM-sponsored PCOS consensus workshop group.17All 
diagnoses were made by an experienced ultrasonographer. 
The exclusion criteria used when selecting patients 
and controls were as follows: pregnancy; hypothyroidism; 
hyperprolactinemia; Cushing’s syndrome; non-classical 
congenital adrenal hyperplasia; current or previous 
(within the last 6 months) use of oral contraceptives, 
glucocorticoids, anti-androgens, ovulation induction agents, 
other hormones, or anti-diabetic/anti-obesity drugs; patients 
with hyperandrogenism alone; history of any neoplasia; and 
any type of kidney disease or use of anti-hypertensive drugs. 
A complete physical examination was performed on 
all subjects, including measurement of height, weight, 
heart rate, and systolic (SBP) and diastolic (DBP) blood 
pressure by standard methods. The BMI was calculated as 
weight in kg/height in square meters for all subjects. Waist 
circumference, taken midway between the lowest rib and the 
iliac crest, and hip circumference, taken at the level of the 
greater trochanters, was measured to the nearest millimeter 
using a flexible tape.
Blood samples
All blood samples were taken in the morning after a 12-h 
fast. Serum samples were stored at -80°C until the analysis 
date. Fasting blood glucose, serum C-reactive protein (CRP), 
uric acid, alanine amino transferase (ALT), aspartate amino 
transferase (AST), gamma-glutamyl transferase (GGT), 
alkaline phosphatase (ALP), total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), triglycerides, follicule stimulating 
hormone (FSH), luteinizing hormone (LH), and insulin 
levels were measured. 
The homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated by the following formula (18):
HOMA-IR= fasting insulin (mU/ml) x fasting glucose 
(mmol/l)/22.5.
Ambulatory BP monitoring
Ambulatory BP monitoring was obtained from every 
subject with a portable, automated noninvasive monitoring 
device (Space Labs 90207; Spacelabs Inc, Redmond, 
Washington). An appropriately sized ambulatory BP 
measurement (ABPM) cuff was placed on the participant’s 
non-dominant arm, and two readings were manually 
initiated. Readings were repeated if the SBP or DBP fell 
outside the predefined acceptable ranges (SBP: 70-240 
mmHg; DBP: 40-150 mmHg; and heart rate: 20-150 beats/
min). During BP recordings, participants were instructed 
to keep their arms still and in an extended position. The 
monitors were programmed to record BP every 30 minutes 
throughout the 24-hour period.
The periods of daytime and nighttime were determined 
based on the actual waking and sleep times recorded in 
the subjects’ individual diaries. The average BP during 
daytime and nighttime was calculated. Subjects were 
defined as “dippers” when their nighttime SBP fell by 477
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10% or more compared to the daytime SBP. Likewise, 
subjects were defined as non-dippers when their SBP fell 
by <10% compared to daytime SBP or rose above daytime 
SBP(reverse dipping). 
Statistical analysis
The data were analyzed using the Student’s t-test to 
determine whether differences were significant. P<0.05 was 
considered statistically significant. All calculations were 
carried out with SPSS version 13 (SPSS, Chicago, IL).
RESULTS
The study group was composed of 168 women (mean 
age: 25.7± 5.5) who were diagnosed with PCOS, while the 
control group included 52 age- and BMI-matched healthy 
subjects (mean age: 26.1±.4) Table 1 lists the descriptive 
data of patients and controls. 
There was no statistically significant difference between 
PCOS patients and the control group with respect to the 
lipid profile, including total cholesterol, triglyceride, and 
HDL and LDL cholesterol levels. Although there was no 
statistically significant difference in fasting blood glucose 
levels between the two groups, as expected, the HOMA-IR 
values of the PCOS group were statistically significantly 
higher than the values of the control group (2.5 vs. 1.3, 
respectively, p=0.02); waist circumference showed the same 
trend (90.6±12.8 cm vs. 78.5±9.3 cm, respectively, p=0.02). 
Moreover, the non-dipping BP patterns were significantly 
more common in PCOS patients compared to the control 
group (p<0.01). The prevalence of a non-dipping BP pattern 
was 43.4% (73 patients) in PCOS patients and 3.9% (2 
patients) in the control group. The calculated power of the 
study was 99.2%. 
DISCUSSION
We found a significantly increased prevalence of a non-
dipping BP pattern in PCOS patients compared to age- and 
BMI-matched controls. Because the PCOS subjects and 
matching controls had similar BMI values (26.8 and 25.4, 
respectively), this increased prevalence of non-dipping BP 
changes cannot be attributed to the increased BMI. Similar 
to our results, Arslanian et al. demonstrated that adolescents 
with PCOS and impaired glucose tolerance lacked the 
normal nocturnal decline in BP.19
It is also interesting that there was no statistically 
significant difference between PCOS and control group 
patients with respect to the lipid profile, including total 
cholesterol, triglyceride, and HDL and LDL cholesterol 
levels, which were in the normal range in both groups. 
This finding may be ascribed to the young age of our study 
participants and their active life styles. 
The increased risk of cardiovascular disease in 
patients with PCOS is still controversial because sufficient 
epidemiological data are not present.20,21 Moreover, 24-hour 
ambulatory SBP measurements revealed higher BP values 
in women with PCOS compared with controls, which may 
be evidence for the development of continual hypertension 
later in life.22 However, to the best of our knowledge, the 
non-dipping BP pattern has rarely been studied in PCOS 
patients. In contrast, the association of insulin resistance and 
non-dipping BP pattern has been investigated in few studies. 
In patients with metabolic syndrome, another consequence 
of insulin resistance, a decrease in the normal nocturnal BP 
decline, has been clearly defined.23
Although BMI and lipid profile were in the normal range, 
the prevalence of the non-dipping BP pattern was 43.4% 
(73 patients) in PCOS patients, which is a very high rate 
Table 1 - Descriptive data of the study group and healthy 
control subjects.
Variable PCOS 
(n: 168)
Control 
(n: 52) 
P value
Age (yr)  25.7± 5.5 26.1±5.4 >0.05
Waist circumference (cm) 90.6±12.8 78.5±9.3 0.02
BMI (kg/m2) 26.8±3.4 25.4±2.8 >0.05
ALT (units/l) 18.5±6.7 17.1±5.4 >0.05
AST (units/l) 17.3±6.5 16.3±5.6 >0.05
GGT (units/l) 17.2±7.4 16.4±6.2 >0.05
ALP (units/l) 66.1±13.4 55.7±10.4 >0.05
Triglyceride (mg/dl) 90.9±28.2 89.0±22.5 >0.05
Total cholesterol (mg/dl) 168.7±36.7 162.7±32.2 >0.05
HDL-C (mg/dl) 55.5±9.7 54.7±7.4 >0.05
LDL-C (mg/dl) 91.9±22.3 91.2±26.7 >0.05
CRP (mg/l) 5.6±3.8 5.1±2.7 >0.05
Urea (mg/dl) 24.8±4.7 23.9±5.4 >0.05
Creatinine (mg/dl) 0.61±0.1 0.59±0.1 >0.05
HOMA-IR 2.5±1.4 1.3±0.9 0.02
Non-dipping status preva-
lence
43.4% 3.9% <0.01
Daytime SBP 113.8±10.8 96.0±9.7 <0.01
Daytime DBP 75.9±6.3 66.3±6.5 0.02
Nighttime SBP 105.4±13.8 88.0±2.3 <0.01
Nighttime DBP 70.0±7.8 57.2±5.4 0.02
Data are mean ± SD, unless specified otherwise. BMI, body mass index; 
CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate ami-
notransferase GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.478
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compared to normal population. Currently, the incidence 
of cardiovascular diseases not only increases non-dippers, 
but its prognosis also worsens.24-26 Gorostidi et al. found the 
presence of non-dipping BP pattern to be as high as 56.6% 
in a population with a high cardiovascular risk.27
A non-dipping BP pattern is regarded as an independent 
predictor of future cardiovascular events.28 Moreover, it is 
also associated with left ventricular hypertrophy and renal 
dysfunction.29,30 Because the main determinant of the circadian 
variations in BP appears to be the sympathetic nervous 
system, this system is suspected in the pathophysiology of the 
non-dipping BP pattern.31 Vascular endothelial dysfunction is 
another pathophysiological mechanism commonly suspected 
to play a role in the non-dipping blood pressure pattern.32 
Whatever the underlying mechanisms, the diseases that 
predispose to a blunted nocturnal BP fall must be diagnosed 
earlier and follow-up is essential. 
In some previous studies, insulin resistance was the 
most important feature of PCOS.33,34 Supporting our data, a 
relationship between insulin resistance and a non-dipping 
BP pattern was previously demonstrated.35 Furthermore, the 
cardiovascular risk in PCOS patients is correlated with the 
degree of hyperinsulinemia.36 Our findings further support 
these data based on the fact that non-dipping BP changes are 
more common in the PCOS group than controls. Although 
HOMA-IR values were statistically significantly different 
from the controls, the lipid profile and BMI were not. 
Another very important and interesting finding of our 
study was that, although the BMI of the two groups were 
similar, there was a statistically significant difference 
between PCOS patients and the control group in regards 
to the waist circumference. Similarly, Dewailly et al. 
reported that waist circumference is one of the most reliable 
measurements of increased abdominal adipose tissue and 
positively correlates with insulinemia, insulin resistance, 
and both plasma luteinizing hormone and estradiol levels.37 
Increased waist circumference is an independent risk factor 
for hypertension.38 Waist circumference is also important 
because it is one of the major components of metabolic 
syndrome, which is also clearly associated with increased 
cardiovascular disease risk. 
In conclusion, our cross-sectional study revealed that a 
non-dipping BP pattern is highly prevalent in PCOS patients, 
even if they are young and non-obese. Although the cross-
sectional study design does not permit us to determine a 
cause-and-effect relationship and the mechanisms linking 
these two diseases are unclear, insulin resistance is the 
most suspected pathway. Moreover, the difference in the 
waist circumferences of the two groups may also play an 
additional role in BP changes. Further prospective studies 
are warranted not only to verify this relationship but also to 
elucidate the exact mechanisms. 
REFERENCES
1.  Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary 
syndrome: towards a rational approach. In: Dunaif A, Givens JR, 
Haseltine FP, Merriam GR, editors. Polycystic Ovary Syndrome. Oxford, 
England: Blackwell Scientific. 1992;377-84.
2.  Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. 
The prevalence and features of the polycystic ovary syndrome in an 
unselected population. J Clin Endocrinol Metab. 2004;89:2745-9.
3.  Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the 
risk of spontaneous abortion following assisted reproductive technology 
treatment. Hum Reprod. 2001;16:2606-9.
4.  Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing 
metformin through pregnancy in women with polycystic ovary syndrome 
appears to safely reduce first-trimester spontaneous abortion: a pilot 
study. Fertil Steril. 2001;75:46-52.
5.  Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone 
B, et al. Visceral fat is associated with cardiovascular risk in women 
with polycystic ovary syndrome. Hum Reprod. 2008;23:153-9.
6.  Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein 
GD, et al. Postmenopausal women with a history of irregular menses and 
elevated androgen measurements at high risk for worsening cardiovascular 
event-free survival: results from the National Institutes of Health– National 
Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome 
Evaluation. J Clin Endocrinol. Metab. 2008;93:1276-84.
7.  Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo 
T, et al. Early impairment of endothelial structure and function in 
young normal-weight women with polycystic ovary syndrome. J Clin 
Endocrinol Metab. 2004;89:4588-93.
8.  Talbott EO, Zborowski J V, Rager J R, Boudreaux MY, Edmundowicz 
DA, Guzick DS. Evidence for an association between metabolic 
cardiovascular syndrome and coronary and aortic calcification among 
women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 
2004;89:5454-61.
9.  Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis 
I, Paterakis T, et al. Inflammatory and endothelial markers in women 
with polycystic ovary syndrome. Eur J Clin Invest. 2006;36:691-7.
10.  Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L, et al. 
Serum C-reactive protein in polycystic ovary syndrome 355 The plasma 
homocystein levels are increased in polycystic ovary syndrome. Gynecol 
Obstet Invest. 2002;53:157-62.
11.  Guo L, Hu XS, Guo ZR, Kang GD, Wu M, Zhou H. [Association 
and interaction between the components of metabolic syndrome 
and cardiovascular disease]. Zhonghua Xin Xue Guan Bing Za Zhi. 
2009;37:644-7.
12.  Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal 
blood pressure variation and all-cause mortality. Am J Hypertens. 
2008;21:92-7.479
CLINICS 2010;65(5):475-9 Polycystic ovary syndrome and non-dipping BP
Kargili A et al.
Copyright © 2010 CLINICS
13.  Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. 
Superiority of ambulatory over clinic blood pressure measurement 
in predicting mortality: The Dublin outcome study. Hypertension. 
2005;46:156-61.
14.  Higashi Y, Nakagawa K, Kimura M, Noma K, Hara K, Sasaki S, et al. 
Circadian variation of blood pressure and endothelial function in patients 
with essential hypertension: a comparison of dippers and non-dippers. 
J Am Coll Cardiol. 2002;40:2039-43.
15.  Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous 
function in non-dipper essential hypertensive subjects: evaluation 
by power spectral analysis of heart rate variability. Hypertension. 
1995;26:808-14.
16.  Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos 
N. Impact of obesity on 24-hour ambulatory blood pressure and 
hypertension. Hypertension. 2005;45:602-7.
17.  The Rotterdam ESHRE/ASRM–Sponsored PCOS consensus workshop 
group. Revised 2003 consensus on diagnostic criteria and long-term 
health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 
2004;19:41-7. 
18.  Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San 
Antonio heart study. Diabetes Care. 1997;20:1087-92.
19.  Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese 
adolescents with polycystic ovary syndrome: roles of insulin resistance 
and beta-cell dysfunction and risk of cardiovascular disease. J Clin 
Endocrinol Metab. 2001;86:66-71.
20.  Amowitz LL, Sobel BE. Cardiovascular consequences of polycystic 
ovary syndrome. Endocrinol Metab Clin North Am. 1999;28:439-58.
21.  Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. 
Coronary heart disease risk factors in women with polycystic ovary 
syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821-6.
22.  de Faire U, Lindvall K, Nilsson B. Noninvasive ambulatory 24h blood 
pressures and basal blood pressures predict the development of sustained 
hypertension from a borderline state. Am J Hypertens. 1993;6:149-55.
23.  Hermida RC, Chayán L, Ayala DE, Mojón A, Domínguez MJ, Fontao 
MJ, et al. Association of metabolic syndrome and blood pressure 
nondipping profile in untreated hypertension. Am J Hypertens. 
2009;22:307-13. 
24.  Pickering TG. The clinical significance of diurnal blood pressure 
variations. Dippers and nondippers. Circulation. 1990;81:700-2.
25.   Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli 
M, et al. Ambulatory blood pressure variations and silent cerebrovascular 
damage in elderly patients with hypertension. J Hypertension. 
1992;10:875-8.
26.  Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, 
et al. Task Force II: blood pressure measurement and cardiovascular 
outcome. Blood Press Monit. 2001;6:355-70.
27.  Gorostidi M, Sobrino J, Segura J, Sierra C, de la Sierra A, Hernandez 
del Rey R, et al. Ambulatory blood pressure monitoring in hypertensive 
patients with high cardiovascular risk: a cross-sectional analysis of a 20 
000-patient database in Spain. J Hypertens 2007; 25:977-84.
28.  Lakka M, Laaksonen E, Lakka A, Niskanen K, Kompusalo E, 
Tuomilehto J, et al. The metabolic syndrome and total cardiovascular 
disease mortality in middle-aged men. J Am Med Assoc. 2002;288:2709-
16.
29.  Lind L, Andersson PE, Andern B, Hanni A, Lithell HO. Left ventricular 
hypertrophy in hypertension is associated with insulin-resistance 
metabolic syndrome. J Hypertens. 1995; 13:433-8.
30.  Palaniappan L, Carnethon M, Fortmann SP. Association between 
microalbuminouria and the metabolic syndrome: NHANES III. Am J 
Hypertens. 2003;16:952-8. 
31.  Sica DA. What are the influences of salt, potassium, the sympathetic 
nervous system, and the renin-angiotensin system on the circadian 
variation in blood pressure? Blood Press Monit. 1999;4:9-16.
32.  Ekmekci H, Ekmekci OB. The role of adiponectin in atherosclerosis 
and thrombosis. Clin Appl Thromb Hemost. 2006;12:163-8.
33.  Mahabeer S, Jialal I, Norman RJ, Naidoo C, Reddi K, Joubert SM. 
Insulin and C-peptide secretion in non-obese patients with polycystic 
ovarian disease. Hormone Metab Res. 1989;21:502-6.
34.   Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush 
A, et al. The relationship of insulin sensitivity to menstrual pattern in 
women hyperandrogenism and polycystic ovaries. Clin Endocrinol. 
1993;39:351-5.
35.  Nakano S, Kitazawa M, Tsuda S, Himeno M, Makiishi H, Nakagawa 
A, et al. Insulin resistance is associated with reduced nocturnal falls of 
blood pressure in normotensive, nonobese type 2 diabetic subjects. Clin 
Exp Hypertens. 2002;24:65-73.
36.  Goodarzi MO, Korenman SG. The importance of insulin resistance in 
polycystic ovary syndrome. Fertil Steril. 2003;80:72-6.
37.  Dewailly D, Cortet-Rudelli C, Deroubaix-Allard D. Markers of 
abdominal adipose tissue in women: relationship to ovarian function. 
Trends Endocrinol Metab. 1998;9:68-71.
38.  Gilardini L, Parati G, Sartorio A, Mazzilli G, Pontiggia B, Invitti C. 
Sympathoadrenergic and metabolic factors are involved in ambulatory 
blood pressure rise in childhood obesity. J Hum Hypertens. 2008;22:75-
82. 